N-(3-chlorophenyl)-4-naphthalen-2-yl-1,3-thiazol-2-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(3-chlorophenyl)-4-naphthalen-2-yl-1,3-thiazol-2-amine
• 化学式: C₁₉H₁₃ClN₂S
• 分子量: 336.8
• InChiKey: AAOIRRUGPALZTO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  53.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Compounds and Uses Thereof in Modulating Amyloid Beta
  申请人：Cheng Soan

  公开号：US20070260058A1

  公开（公告）日：2007-11-08

  Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.

  本发明提供了新的化合物、组合物和试剂盒。还提供了调节Aβ水平的方法以及治疗与异常Aβ水平相关的疾病的方法。
• COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA
  申请人：Cheng Soan

  公开号：US20100324032A1

  公开（公告）日：2010-12-23

  Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.

  本发明提供了新型化合物、组合物和试剂盒。还提供了调节Aβ水平的方法和治疗与异常Aβ水平相关的疾病的方法。
• Compounds Having Activity in Correcting Mutant-Cftr Processing and Uses Thereof
  申请人：Verkman Alan

  公开号：US20080318984A1

  公开（公告）日：2008-12-25

  The invention provides compositions, pharmaceutical preparations and methods for correcting cellular processing (e.g., folding, trafficking, or post-translational modification) of a mutant-cystic fibrosis transmembrane conductance regulator protein (e.g., ΔF508 CFTR) that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more aminobenzothiazole-containing compounds, aminoarylthiazole-containing compounds, quinazolinylaminopyrimidinone-containing compounds, bisaminomethylbithiazole-containing compounds, or phenylaminoquino-line-containing compounds of the invention, or an analog or derivative thereof.
• A CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE
  申请人：UNIVERSITA' DEGLI STUDI DI PADOVA

  公开号：US20150328217A1

  公开（公告）日：2015-11-19

  The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic Ventricular Tachycardia (CPVT).
• CFTR CORRECTOR FOR THE TREATMENT OF GENETIC DISORDERS AFFECTING STRIATED MUSCLE
  申请人：UNIVERSITA' DEGLI STUDI DI PADOVA

  公开号：US20180221347A1

  公开（公告）日：2018-08-09

  The present invention relates to the use of CFTR correctors in the treatment of genetic disorders affecting striated muscle selected from sarcoglycanopathies, Brody's disease (BD) and the recessive forms of Cathecolaminergic Polymorphic Ventricular Tachycardia (CPVT).